NCT00994292
Completed
Phase 2
A Randomized, Double-Blind, Placebo Controlled Multi-Center and Parallel Group Study of the Safety, Tolerability and Efficacy of YM150 in Combination With Standard Treatment in Secondary Prevention of Ischemic Vascular Events in Subjects With Acute Coronary Syndromes
Overview
- Phase
- Phase 2
- Intervention
- YM150
- Conditions
- Acute Coronary Syndrome
- Sponsor
- Astellas Pharma Europe B.V.
- Enrollment
- 1276
- Primary Endpoint
- Incidence of Major and Clinically Relevant Non Major bleeding events according to International Society of Thrombosis and Hemostasis (ISTH) definition
- Status
- Completed
- Last Updated
- 10 years ago
Overview
Brief Summary
The purpose of this study is to evaluate the safety and efficacy of various doses of YM150 (the experimental drug) in the prevention of ischemic vascular events in subjects with recent acute coronary syndromes.
Investigators
Eligibility Criteria
Inclusion Criteria
- •has a diagnosis of STE-ACS, NSTE-ACS as index event according to accepted guidelines such as the ESC or AHA guidelines
- •has elevated cardiac biomarkers
Exclusion Criteria
- •is planned for myocardial revascularization (e.g., Coronary Artery Bypass Graft (CABG) or elective or staged PCI) or any other invasive procedure with increased risk for bleeding (i.e. elective surgical procedures) within 60 days after randomization
- •has had recent stroke or TIA ≤ 12 months prior to index event
- •has persistent BP of 160 mmHg systolic or higher and/or 100 mmHg diastolic or higher at baseline with or without medication
- •has participated in another clinical trial of an investigational drug (including placebo) or device within 30 days (or the limit set by national law, whichever is longer) of signing informed consent for the present study
- •has participated in any YM150 clinical trials
- •requires ongoing parenteral or oral anticoagulant therapy
- •has active bleeding or is in the opinion of the investigator at high risk of bleeding during the study
Arms & Interventions
1. YM150 Dose V, twice daily
Intervention: YM150
2. YM150 Dose W, once daily
Intervention: YM150
3. YM150 Dose X, twice daily
Intervention: YM150
4. YM150 Dose Y, once daily
Intervention: YM150
5. YM150 Dose Y, twice daily
Intervention: YM150
6. YM150 Dose Z, once daily
Intervention: YM150
7. Placebo
Intervention: Placebo
Outcomes
Primary Outcomes
Incidence of Major and Clinically Relevant Non Major bleeding events according to International Society of Thrombosis and Hemostasis (ISTH) definition
Time Frame: 6 Months
Secondary Outcomes
- Incidence of Major and Clinically Relevant Non Major bleeding events(30 Days)
Similar Trials
Completed
Phase 2
A Study Evaluating Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects Undergoing Hip Replacement SurgeryVenous ThromboembolismArthroplasty, Replacement, HipNCT00902928Astellas Pharma Europe B.V.1,992
Completed
Phase 3
A Study to Assess the Effect of YM150 for Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal SurgeryVenous ThromboembolismNCT00942435Astellas Pharma Inc156
Completed
Phase 2
A Study Evaluating Safety and Tolerability of YM150 Compared to Warfarin in Subjects With Atrial FibrillationAtrial FibrillationNCT00938730Astellas Pharma Inc1,280
Completed
Phase 2
Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement SurgeryVenous ThromboembolismNCT00917254Astellas Pharma Inc369
Completed
Phase 2
Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement SurgeryVenous ThromboembolismNCT00913120Astellas Pharma Inc610